Industry Growth Insights published a new data on “RNA Interference (RNAi) Drug Delivery Market”. The research report is titled “RNA Interference (RNAi) Drug Delivery Market research by Types (Nanoparticle Drug Delivery Technology, Pulmonary Drug Delivery Technology, Nucleic Acid Drug Delivery Technology, Aptamer Drug Delivery Technology), By Applications (Infectious Diseases, Cardiology, Oncology, Neurology, Ophthalmology, Metabolic Disorders), By Players/Companies Metabolic disorders, Alnylam Pharmaceuticals Inc, Merck & Co. Inc, Access Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Calondo Pharmaceuticals Inc, Marina Biotech Inc, RXi Pharmaceuticals Corp, Quark Pharmaceuticals Inc, Silence Therapeutics plc, Tacere Therapeutics Inc, PhaseRx Inc, Sirnaomics Inc, Traversa Therapeutics Inc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
RNA Interference (RNAi) Drug Delivery Market Research Report
By Type
Nanoparticle Drug Delivery Technology, Pulmonary Drug Delivery Technology, Nucleic Acid Drug Delivery Technology, Aptamer Drug Delivery Technology
By Application
Infectious Diseases, Cardiology, Oncology, Neurology, Ophthalmology, Metabolic Disorders
By Companies
Metabolic disorders, Alnylam Pharmaceuticals Inc, Merck & Co. Inc, Access Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Calondo Pharmaceuticals Inc, Marina Biotech Inc, RXi Pharmaceuticals Corp, Quark Pharmaceuticals Inc, Silence Therapeutics plc, Tacere Therapeutics Inc, PhaseRx Inc, Sirnaomics Inc, Traversa Therapeutics Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
129
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
 Drug Delivery Industry Outlook.svg)
Global RNA Interference (RNAi) Drug Delivery Market Report Segments:
The global RNA Interference (RNAi) Drug Delivery market is segmented on the basis of:
Types
Nanoparticle Drug Delivery Technology, Pulmonary Drug Delivery Technology, Nucleic Acid Drug Delivery Technology, Aptamer Drug Delivery Technology
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Infectious Diseases, Cardiology, Oncology, Neurology, Ophthalmology, Metabolic Disorders
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Metabolic disorders
- Alnylam Pharmaceuticals Inc
- Merck & Co. Inc
- Access Pharmaceuticals Inc
- Dicerna Pharmaceuticals Inc
- Calondo Pharmaceuticals Inc
- Marina Biotech Inc
- RXi Pharmaceuticals Corp
- Quark Pharmaceuticals Inc
- Silence Therapeutics plc
- Tacere Therapeutics Inc
- PhaseRx Inc
- Sirnaomics Inc
- Traversa Therapeutics Inc
 Drug Delivery Market Overview.svg)
Highlights of The RNA Interference (RNAi) Drug Delivery Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Nanoparticle Drug Delivery Technology
- Pulmonary Drug Delivery Technology
- Nucleic Acid Drug Delivery Technology
- Aptamer Drug Delivery Technology
- By Application:
- Infectious Diseases
- Cardiology
- Oncology
- Neurology
- Ophthalmology
- Metabolic Disorders
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the RNA Interference (RNAi) Drug Delivery Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Drug Delivery Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
RNA interference (RNAi) drug delivery is a novel approach to delivering drugs to specific cells or tissues. RNAi technology uses small interfering RNAs (siRNAs) to target and destroy the messenger RNA (mRNA) of genes that are responsible for gene expression. siRNAs can be delivered directly into cells using various methods, including transfection, liposomes, and viral vectors. Once inside the cell, the siRNAs bind to the mRNA molecules and cause them to be degraded or silenced. This disruption in gene expression leads to decreased production of proteins by targeted cells or tissues
Some of the major companies in the rna interference (rnai) drug delivery market are Metabolic disorders, Alnylam Pharmaceuticals Inc, Merck & Co. Inc, Access Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Calondo Pharmaceuticals Inc, Marina Biotech Inc, RXi Pharmaceuticals Corp, Quark Pharmaceuticals Inc, Silence Therapeutics plc, Tacere Therapeutics Inc, PhaseRx Inc, Sirnaomics Inc, Traversa Therapeutics Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 RNA Interference (RNAi) Drug Delivery Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 RNA Interference (RNAi) Drug Delivery Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 RNA Interference (RNAi) Drug Delivery Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the RNA Interference (RNAi) Drug Delivery Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global RNA Interference (RNAi) Drug Delivery Market Size & Forecast, 2018-2028
4.5.1 RNA Interference (RNAi) Drug Delivery Market Size and Y-o-Y Growth
4.5.2 RNA Interference (RNAi) Drug Delivery Market Absolute $ Opportunity
Chapter 5 Global RNA Interference (RNAi) Drug Delivery Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 RNA Interference (RNAi) Drug Delivery Market Size Forecast by Type
5.2.1 Nanoparticle Drug Delivery Technology
5.2.2 Pulmonary Drug Delivery Technology
5.2.3 Nucleic Acid Drug Delivery Technology
5.2.4 Aptamer Drug Delivery Technology
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global RNA Interference (RNAi) Drug Delivery Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 RNA Interference (RNAi) Drug Delivery Market Size Forecast by Applications
6.2.1 Infectious Diseases
6.2.2 Cardiology
6.2.3 Oncology
6.2.4 Neurology
6.2.5 Ophthalmology
6.2.6 Metabolic Disorders
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global RNA Interference (RNAi) Drug Delivery Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 RNA Interference (RNAi) Drug Delivery Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America RNA Interference (RNAi) Drug Delivery Analysis and Forecast
9.1 Introduction
9.2 North America RNA Interference (RNAi) Drug Delivery Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America RNA Interference (RNAi) Drug Delivery Market Size Forecast by Type
9.6.1 Nanoparticle Drug Delivery Technology
9.6.2 Pulmonary Drug Delivery Technology
9.6.3 Nucleic Acid Drug Delivery Technology
9.6.4 Aptamer Drug Delivery Technology
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America RNA Interference (RNAi) Drug Delivery Market Size Forecast by Applications
9.10.1 Infectious Diseases
9.10.2 Cardiology
9.10.3 Oncology
9.10.4 Neurology
9.10.5 Ophthalmology
9.10.6 Metabolic Disorders
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe RNA Interference (RNAi) Drug Delivery Analysis and Forecast
10.1 Introduction
10.2 Europe RNA Interference (RNAi) Drug Delivery Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe RNA Interference (RNAi) Drug Delivery Market Size Forecast by Type
10.6.1 Nanoparticle Drug Delivery Technology
10.6.2 Pulmonary Drug Delivery Technology
10.6.3 Nucleic Acid Drug Delivery Technology
10.6.4 Aptamer Drug Delivery Technology
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe RNA Interference (RNAi) Drug Delivery Market Size Forecast by Applications
10.10.1 Infectious Diseases
10.10.2 Cardiology
10.10.3 Oncology
10.10.4 Neurology
10.10.5 Ophthalmology
10.10.6 Metabolic Disorders
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific RNA Interference (RNAi) Drug Delivery Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific RNA Interference (RNAi) Drug Delivery Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific RNA Interference (RNAi) Drug Delivery Market Size Forecast by Type
11.6.1 Nanoparticle Drug Delivery Technology
11.6.2 Pulmonary Drug Delivery Technology
11.6.3 Nucleic Acid Drug Delivery Technology
11.6.4 Aptamer Drug Delivery Technology
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific RNA Interference (RNAi) Drug Delivery Market Size Forecast by Applications
11.10.1 Infectious Diseases
11.10.2 Cardiology
11.10.3 Oncology
11.10.4 Neurology
11.10.5 Ophthalmology
11.10.6 Metabolic Disorders
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America RNA Interference (RNAi) Drug Delivery Analysis and Forecast
12.1 Introduction
12.2 Latin America RNA Interference (RNAi) Drug Delivery Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America RNA Interference (RNAi) Drug Delivery Market Size Forecast by Type
12.6.1 Nanoparticle Drug Delivery Technology
12.6.2 Pulmonary Drug Delivery Technology
12.6.3 Nucleic Acid Drug Delivery Technology
12.6.4 Aptamer Drug Delivery Technology
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America RNA Interference (RNAi) Drug Delivery Market Size Forecast by Applications
12.10.1 Infectious Diseases
12.10.2 Cardiology
12.10.3 Oncology
12.10.4 Neurology
12.10.5 Ophthalmology
12.10.6 Metabolic Disorders
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) RNA Interference (RNAi) Drug Delivery Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) RNA Interference (RNAi) Drug Delivery Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) RNA Interference (RNAi) Drug Delivery Market Size Forecast by Type
13.6.1 Nanoparticle Drug Delivery Technology
13.6.2 Pulmonary Drug Delivery Technology
13.6.3 Nucleic Acid Drug Delivery Technology
13.6.4 Aptamer Drug Delivery Technology
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) RNA Interference (RNAi) Drug Delivery Market Size Forecast by Applications
13.10.1 Infectious Diseases
13.10.2 Cardiology
13.10.3 Oncology
13.10.4 Neurology
13.10.5 Ophthalmology
13.10.6 Metabolic Disorders
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 RNA Interference (RNAi) Drug Delivery Market: Competitive Dashboard
14.2 Global RNA Interference (RNAi) Drug Delivery Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Metabolic disorders
14.3.2 Alnylam Pharmaceuticals Inc
14.3.3 Merck & Co. Inc
14.3.4 Access Pharmaceuticals Inc
14.3.5 Dicerna Pharmaceuticals Inc
14.3.6 Calondo Pharmaceuticals Inc
14.3.7 Marina Biotech Inc
14.3.8 RXi Pharmaceuticals Corp
14.3.9 Quark Pharmaceuticals Inc
14.3.10 Silence Therapeutics plc
14.3.11 Tacere Therapeutics Inc
14.3.12 PhaseRx Inc
14.3.13 Sirnaomics Inc
14.3.14 Traversa Therapeutics Inc
